C4 Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 145

Employees

  • Stock Symbol
  • CCCC

Stock Symbol

  • Share Price
  • $8.98
  • (As of Friday Closing)

C4 Therapeutics General Information

Description

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 490 Arsenal Way
  • Suite 120
  • Watertown, MA 02472
  • United States
+1 (617) 000-0000

C4 Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

C4 Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.98 $8.80 $1.06 - $9.66 $617M 49.3M 15.4M -$2.67

C4 Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 134,051 134,051 63,248 1,186,359
Revenue 20,756 20,756 31,096 45,785
EBITDA (137,772) (137,772) (127,858) (80,642)
Net Income (132,493) (132,493) (128,175) (83,892)
Total Assets 376,451 376,451 430,840 506,765
Total Debt 70,976 70,976 87,152 42,879
Public Fundamental Data provided by Morningstar, Inc. disclaimer

C4 Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore C4 Therapeutics‘s full profile, request access.

Request a free trial

C4 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore C4 Therapeutics‘s full profile, request access.

Request a free trial

C4 Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new gener
Pharmaceuticals
Watertown, MA
145 As of 2023
00000
000000000 00000

000000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehen
0000000000000
New Haven, CT
000 As of 0000
00000
000000000 00000

00000

llamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in
0000 000000000
Boston, MA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

C4 Therapeutics Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arvinas Formerly VC-backed New Haven, CT 000 00000 000000000 00000
Monte Rosa Therapeutics Formerly VC-backed Boston, MA 000 00000 00000000 00000
Forma Therapeutics Corporate Backed or Acquired Watertown, MA 000 00.000 000000&0 00.000
Kymera Therapeutics Formerly VC-backed Watertown, MA 000 00000 00000000 00000
Nurix Therapeutics Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

C4 Therapeutics Patents

C4 Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3174290-A1 Selected compounds for targeted degradation of brd9 Pending 09-Sep-2021
CA-3224732-A1 Compounds for targeting degradation of irak4 proteins Pending 07-Jul-2021 0000000000
AU-2022308734-A1 Compounds for targeting degradation of irak4 proteins Pending 07-Jul-2021
CA-3174245-A1 Therapeutics for the degradation of mutant braf Pending 08-Jun-2021 000000000
AU-2022290851-A1 Therapeutics for the degradation of mutant braf Pending 08-Jun-2021 A61P35/00
To view C4 Therapeutics’s complete patent history, request access »

C4 Therapeutics Executive Team (20)

Name Title Board Seat Contact Info
Andrew Hirsch Chief Executive Officer & Board Member
Kendra Adams Chief Financial Officer, Finance & Treasurer, Finance
Jolie Siegel JD Secretary, Administration & Chief Legal Officer, Legal
Kelly Schick Chief People Officer
Stewart Fisher Ph.D Chief Scientific Officer
You’re viewing 5 of 20 executive team members. Get the full list »

C4 Therapeutics Board Members (16)

Name Representing Role Since
Andrew Hirsch C4 Therapeutics Chief Executive Officer & Board Member 000 0000
Bruce Downey JD Self Chairman & Board Member 000 0000
Ken Anderson MD C4 Therapeutics Board Member & Member of Scientific Advisory Board 000 0000
Malcolm Salter C4 Therapeutics Board Member 000 0000
Nathanael Gray Ph.D Self Co-Founder & Scientific Advisory Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

C4 Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

C4 Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore C4 Therapeutics‘s full profile, request access.

Request a free trial

C4 Therapeutics ESG

Risk Overview

Risk Rating

Updated May, 24, 2023

25.16 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,708

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 884

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 399

Rank

00.00

Percentile

To view C4 Therapeutics’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »